润都股份(002923.SZ)：沙库巴曲缬沙坦钠获得化学原料药上市申请批准通知书

Core Viewpoint - Rundu Co., Ltd. (002923.SZ) has received approval from the National Medical Products Administration for the marketing application of Sacubitril/Valsartan Sodium, a novel heart failure treatment drug [1] Group 1: Product Information - Sacubitril/Valsartan Sodium (brand name: Entresto®) is a new type of heart failure medication originally developed by Novartis, which received FDA approval in 2015 [1] - The drug is indicated for adult patients with reduced ejection fraction chronic heart failure (NYHA class II-IV, LVEF ≤ 40%), aimed at reducing the risk of cardiovascular death and heart failure hospitalization [1] - Sacubitril/Valsartan Sodium can replace ACE inhibitors or ARBs and is used in combination with other heart failure treatments such as beta-blockers, diuretics, and mineralocorticoid receptor antagonists [1] Group 2: Regulatory Approval - The National Medical Products Administration officially approved the drug for marketing in China in July 2017 [1]